This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

24 May 2011

Lilly Signs Agreements to Form Biotech Company

Eli Lilly and private investors Care Capital and NovaQuest Capital agreed to jointly create a biotechnology company to focus on Lilly's severe sepsis drug Xigris.

Eli Lilly and Company has signed agreements with private investors Care Capital and NovaQuest Capital to establish BioCritica Inc., a newly-formed and privately-held biotechnology company.


BioCritica will initially focus on the continued U.S. development and commercialization of Xigris, Lilly's medicine for severe sepsis. BioCritica intends to ultimately build a broad portfolio of innovative, hospital-based critical care medicines.


As part of a licensing agreement, BioCritica will acquire the U.S. development and commercialization rights to Xigris and will also receive the rights to potentially acquire several critical care compounds currently in pre-clinical development at Lilly. The collaboration also includes a supply agreement, a services agreement and an op

Related News